Marker Therapeutics' Losses Widen Amid R&D Spend, Cash Runway Shortens

TL;DR

**MRKR is burning cash faster than it can raise it, making it a high-risk bet on future clinical success and further dilution.**

AI Summary

Marker Therapeutics, Inc. (MRKR) reported a net loss of $10,460,410 for the nine months ended September 30, 2025, a significant increase from the $6,893,691 net loss in the same period of 2024. This was primarily driven by a rise in research and development expenses to $9,658,322 in 2025 from $8,381,661 in 2024, and a $453,135 loss on early termination of a vendor agreement. Grant income, a primary revenue source, decreased to $2,443,225 for the nine months ended September 30, 2025, from $4,339,317 in the prior year. The company's cash, cash equivalents, and restricted cash stood at $18,942,953 as of September 30, 2025. MRKR raised $9,863,883 in net proceeds from the sale of 5,358,292 common shares through an At-The-Market (ATM) agreement in July and August 2025, and an additional $14.9 million from a private placement in December 2024. Despite these capital raises, the company anticipates it can fund operations only through the third quarter of 2026, raising substantial doubt about its ability to continue as a going concern without further financing or grant funds.

Why It Matters

Marker Therapeutics' widening net loss and reliance on dilutive equity financing, like the recent ATM sales, signal significant financial challenges for investors. The company's ability to fund operations only through Q3 2026, despite recent capital raises, highlights a precarious cash runway, which could lead to further stock dilution or operational constraints. For employees and customers, this financial instability could impact job security and the long-term viability of their innovative T-cell therapies, especially given the competitive landscape in immuno-oncology. The broader market will watch to see if MRKR can secure additional non-dilutive funding or strategic partnerships to advance its clinical programs, particularly MT-601 for lymphoma and pancreatic cancer, against larger, better-funded competitors.

Risk Assessment

Risk Level: high — Marker Therapeutics reported a net loss of $10,460,410 for the nine months ended September 30, 2025, and anticipates it can fund its operating expenses only through the third quarter of 2026. This short cash runway, coupled with a significant accumulated deficit of $457,477,588, raises substantial doubt about the company's ability to continue as a going concern, as explicitly stated in Note 3.

Analyst Insight

Investors should exercise extreme caution and consider the high risk of further dilution or potential insolvency. Monitor closely for announcements regarding new grant funding or strategic partnerships, as these are critical for extending the company's cash runway beyond Q3 2026. Without such developments, the stock faces significant downside pressure.

Financial Highlights

debt To Equity

0.18

revenue

$2,443,225

operating Margin

-450.5%

total Assets

$21,734,830

total Debt

$3,345,937

net Income

-$10,460,410

eps

-$0.75

gross Margin

N/A

cash Position

$18,942,953

revenue Growth

-43.7%

Revenue Breakdown

Key Numbers

• $10.46M — Net Loss (Increased from $6.89M in prior year for nine months ended Sep 30, 2025)
• $18.9M — Cash, Cash Equivalents, and Restricted Cash (As of September 30, 2025, down from $19.19M at Dec 31, 2024)
• $9.86M — Net Proceeds from ATM Sales (From 5,358,292 common shares sold in July and August 2025)
• $14.9M — Net Proceeds from Private Placement (Closed December 23, 2024)
• $9.66M — Research and Development Expenses (For nine months ended Sep 30, 2025, up from $8.38M in prior year)
• $2.44M — Grant Income (For nine months ended Sep 30, 2025, down from $4.34M in prior year)
• 16,673,127 — Common Shares Outstanding (As of November 6, 2025, up from 10,709,005 at Jan 1, 2025)
• $457.48M — Accumulated Deficit (As of September 30, 2025, indicating significant historical losses)
• Q3 2026 — Cash Runway (Anticipated period company can fund operations without additional capital)
• 3.0% — ATM Commission Rate (Paid to H.C. Wainwright & Co. LLC)

Key Players & Entities

• Marker Therapeutics, Inc. (company) — registrant
• H.C. Wainwright & Co. LLC (company) — underwriter for ATM offering
• Baylor College of Medicine (company) — supplier of MT-601
• Cellipont Bioservices (company) — CDMO for MT-601 manufacturing
• Cancer Prevention and Research Institute of Texas (regulator) — grant provider (CPRIT)
• U.S. Food and Drug Administration (regulator) — grant provider (FDA)
• National Institutes of Health (regulator) — grant provider (NIH SBIR)
• MT-601 (product) — lead Multi-Antigen Recognizing (MAR)-T cell therapy
• MT-401 (product) — product candidate for AML
• The Nasdaq Stock Market LLC (regulator) — exchange where common stock is registered

FAQ

Risk Factors

• Going Concern Uncertainty [high — financial]: The company anticipates it can fund operations only through Q3 2026, raising substantial doubt about its ability to continue as a going concern without further financing or grant funds. This is exacerbated by increasing net losses and declining grant income.
• Increased R&D Expenses [medium — operational]: Research and development expenses rose to $9,658,322 for the nine months ended September 30, 2025, from $8,381,661 in the prior year. While necessary for development, this increase contributes to the widening net loss.
• Loss on Vendor Agreement Termination [low — operational]: A one-time charge of $453,135 for the early termination of a vendor agreement contributed to the increased operating expenses and net loss for the nine months ended September 30, 2025.
• Declining Grant Income [high — financial]: Grant income, a primary revenue source, decreased to $2,443,225 for the nine months ended September 30, 2025, from $4,339,317 in the prior year, reducing the company's primary funding stream.
• Dilution from Equity Issuances [medium — financial]: The company issued 5,358,292 common shares through an ATM agreement in July/August 2025, increasing shares outstanding from 10,709,005 to 16,673,127. This dilutes existing shareholders' ownership.

Industry Context

Marker Therapeutics operates in the highly competitive and capital-intensive biotechnology sector, focusing on developing novel cell therapies. The industry is characterized by long development cycles, high R&D costs, and significant regulatory hurdles. Success often depends on securing substantial funding for clinical trials and navigating complex approval processes.

Regulatory Implications

As a biotechnology company, MRKR is subject to stringent regulations from bodies like the FDA. Delays in clinical trials, failure to meet efficacy or safety standards, or changes in regulatory requirements could significantly impact its development pipeline and ability to bring products to market.

What Investors Should Do

1. Monitor future capital raises and grant funding.
2. Analyze the drivers of increased R&D expenses.
3. Evaluate the sustainability of the business model.
4. Assess the impact of share dilution.

Key Dates

• 2024-12-23: Private Placement Closed — Raised $14.9 million in net proceeds, providing crucial capital.
• 2025-07-01: ATM Agreement Sales Began — Initiated sales of common shares to raise capital, resulting in $9.86 million net proceeds by August 2025.
• 2025-09-30: End of Nine-Month Period — Reporting period for the 10-Q, showing increased net loss and reduced cash runway.
• 2026-09-30: Anticipated Cash Runway End — Indicates the company's expected operational funding limit without further capital infusion, raising going concern doubts.

Glossary

At-The-Market (ATM) Agreement

A type of equity offering where a company sells shares directly into the open market over a period of time, typically through a broker. (MRKR utilized this to raise $9.86 million in net proceeds, increasing its share count and potentially diluting existing shareholders.)

Going Concern

An accounting principle that assumes a company will continue to operate for the foreseeable future. If there is substantial doubt, it must be disclosed. (The company's financial situation raises substantial doubt about its ability to continue as a going concern, a critical disclosure for investors.)

Accumulated Deficit

The cumulative net losses of a company since its inception, minus any accumulated profits. A negative number indicates the company has never been profitable. (MRKR has an accumulated deficit of $457.48 million as of September 30, 2025, highlighting its history of losses.)

Grant Income

Revenue received from government grants or other non-commercial funding sources, often for research or specific projects. (This is a primary revenue source for MRKR, and its significant decrease in the current period is a major concern.)

Restricted Cash

Cash that a company cannot freely use because it is pledged as collateral for loans or required to be held for specific purposes. (The increase in restricted cash from $0 to $1,352,975 indicates potential new obligations or collateral requirements.)

Year-Over-Year Comparison

For the nine months ended September 30, 2025, Marker Therapeutics reported a net loss of $10.46 million, a significant increase from $6.89 million in the prior year. Total revenues, primarily grant income, decreased by 43.7% to $2.44 million from $4.34 million. Research and development expenses rose by 15.2% to $9.66 million. The company's cash position remains substantial at $18.94 million, but its cash runway is limited to Q3 2026, raising going concern doubts not present to this degree in the prior period.

Key Financial Figures

• $0.001 — ch registered Common Stock, par value $0.001 per share MRKR The Nasdaq Stock Mar
• $250,000 — Corporation ("FDIC") insured limits of $250,000. As of September 30, 2025, the Company

Filing Documents

• mrkr-20250930x10q.htm (10-Q) — 1229KB
• mrkr-20250930xex31d1.htm (EX-31.1) — 13KB
• mrkr-20250930xex31d2.htm (EX-31.2) — 13KB
• mrkr-20250930xex32d1.htm (EX-32.1) — 7KB
• mrkr-20250930xex32d2.htm (EX-32.2) — 7KB
• mrkr-20250930x10q001.jpg (GRAPHIC) — 9KB
• mrkr-20250930x10q002.jpg (GRAPHIC) — 43KB
• mrkr-20250930x10q003.jpg (GRAPHIC) — 29KB
• 0001104659-25-111502.txt ( ) — 5259KB
• mrkr-20250930.xsd (EX-101.SCH) — 38KB
• mrkr-20250930_cal.xml (EX-101.CAL) — 23KB
• mrkr-20250930_def.xml (EX-101.DEF) — 148KB
• mrkr-20250930_lab.xml (EX-101.LAB) — 300KB
• mrkr-20250930_pre.xml (EX-101.PRE) — 230KB
• mrkr-20250930x10q_htm.xml (XML) — 772KB

– FINANCIAL INFORMATION

PART I – FINANCIAL INFORMATION 1 Item 1.

Financial Statements (Unaudited)

Financial Statements (Unaudited) 1 Condensed Consolidated Balance Sheets As of September 30, 2025 and December 31, 2024 1 Condensed Consolidated Statements of Operations for the three and nine months ended September 30, 2025 and 2024 2 Condensed Consolidated Statements of Stockholders' Equity for the three and nine months ended September 30, 2025 and 2024 3 Condensed Consolidated Statements of Cash Flows for the nine months ended September 30, 2025 and 2024 4 Notes to Condensed Consolidated Financial Statements 5 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations. 18 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk. 30 Item 4.

Controls and Procedures

Controls and Procedures. 30

– OTHER INFORMATION

PART II – OTHER INFORMATION 31 Item 1. Legal Proceedings. 31 Item 1A. Risk Factors. 31 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds. 32 Item 3. Defaults Upon Senior Securities. 32 Item 4. Mine Safety Disclosure. 32 Item 5. Other Information. 32 Item 6. Exhibits. 33

Signatures

Signatures 35 Table of Contents

FINANCIAL INFORMATION

PART I. FINANCIAL INFORMATION

Financial Statement s

Item 1. Financial Statement s MARKER THERAPEUTICS, INC. CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) September 30, December 31, 2025 2024 ASSETS Current assets: Cash and cash equivalents $ 17,589,978 $ 19,192,440 Restricted cash 1,352,975 — Prepaid expenses and deposits 1,126,724 483,717 Other receivables 1,665,153 2,346,703 Total current assets 21,734,830 22,022,860 Total assets $ 21,734,830 $ 22,022,860 LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities: Accounts payable and accrued liabilities $ 1,664,647 $ 1,753,954 Related party payable 328,315 1,710,500 Deferred revenue 1,352,975 — Total current liabilities 3,345,937 3,464,454 Total liabilities 3,345,937 3,464,454 Stockholders' equity: Preferred stock, $ 0.001 par value, 5 million shares authorized, 0 shares issued and outstanding at September 30, 2025 and December 31, 2024 , respectively — — Common stock, $ 0.001 par value, 30 million shares authorized, 16.7 million and 10.7 million shares issued and outstanding as of September 30, 2025 and December 31, 2024, respectively (see Note 8) 16,672 10,708 Additional paid-in capital 475,849,809 465,564,876 Accumulated deficit ( 457,477,588 ) ( 447,017,178 ) Total stockholders' equity 18,388,893 18,558,406 Total liabilities and stockholders' equity $ 21,734,830 $ 22,022,860 See accompanying notes to these unaudited condensed consolidated financial statements. 1 Table of Contents MARKER THERAPEUTICS, INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) For the Three Months Ended For the Nine Months Ended September 30, September 30, 2025 2024 2025 2024 Revenues: Grant income $ 1,232,938 $ 1,926,020 $ 2,443,225 $ 4,339,317 Total revenues 1,232,938 1,926,020 2,443,225 4,339,317 Operating expenses: Research and development 2,345,843 3,471,216 9,658,322 8,381,661 General and adm

View Full Filing

View this 10-Q filing on SEC EDGAR